Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
Li L, Hobson L, Perry L, Clark B, Heavey S, Haider A, Sridhar A, Shaw G, Kelly J, Freeman A, Wilson I, Whitaker H, Nurmemmedov E, Oltean S, Porazinski S, Ladomery M. Li L, et al. Among authors: haider a. Br J Cancer. 2020 Sep;123(6):1024-1032. doi: 10.1038/s41416-020-0951-2. Epub 2020 Jun 25. Br J Cancer. 2020. PMID: 32581342 Free PMC article.
Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
Thompson JE, Sridhar AN, Tan WS, Freeman A, Haider A, Allen C, Moore CM, Orczyk C, Mazzon G, Khetrapal P, Shaw G, Rajan P, Mohammed A, Briggs TP, Nathan S, Kelly JD, Sooriakumaran P. Thompson JE, et al. Among authors: haider a. J Urol. 2019 Jun;201(6):1134-1143. doi: 10.1097/JU.0000000000000135. J Urol. 2019. PMID: 30730409
PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens.
Heavey S, Costa H, Pye H, Burt EC, Jenkinson S, Lewis GR, Bosshard-Carter L, Watson F, Jameson C, Ratynska M, Ben-Salha I, Haider A, Johnston EW, Feber A, Shaw G, Sridhar A, Nathan S, Rajan P, Briggs TP, Sooriakumaran P, Kelly JD, Freeman A, Whitaker HC. Heavey S, et al. Among authors: haider a. Prostate. 2019 May;79(7):768-777. doi: 10.1002/pros.23782. Epub 2019 Feb 26. Prostate. 2019. PMID: 30807665 Free PMC article.
NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study.
Dinneen E, Haider A, Allen C, Freeman A, Briggs T, Nathan S, Brew-Graves C, Grierson J, Williams NR, Persad R, Oakley N, Adshead JM, Huland H, Haese A, Shaw G. Dinneen E, et al. Among authors: haider a. BMJ Open. 2019 Jun 11;9(6):e028132. doi: 10.1136/bmjopen-2018-028132. BMJ Open. 2019. PMID: 31189680 Free PMC article.
NeuroSAFE PROOF Randomised Controlled Feasibility Study: Brief Report of Perioperative Outcomes, Histological Concordance, and Feasibility.
Dinneen E, Haider A, Freeman A, Oxley J, Briggs T, Nathan S, Kelly J, Grierson J, Allen C, Persad R, Aning J, Oakley N, Ahmad I, Dutto L, Shaw G. Dinneen E, et al. Among authors: haider a. Eur Urol. 2020 Sep;78(3):476-478. doi: 10.1016/j.eururo.2020.03.052. Epub 2020 Apr 25. Eur Urol. 2020. PMID: 32340693 Free article. Clinical Trial. No abstract available.
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis J Urol 2020; doi: 10.1097/JU.0000000000001157.
Stavrinides V, Giganti F, Punwani S, Allen C, Kirkham A, Freeman A, Ball R, Haider A, Whitaker H, Orczyk C, Emberton M, Moore CM. Stavrinides V, et al. Among authors: haider a. J Urol. 2020 Nov;204(5):1065-1066. doi: 10.1097/JU.0000000000001295. Epub 2020 Jul 23. J Urol. 2020. PMID: 32698715 No abstract available.
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S, Simpson BS, Stopka-Farooqui U, Sathyadevan VK, Echeverria LMC, Kumar C, Costa H, Haider A, Freeman A, Jameson C, Ratynska M, Ben-Salha I, Sridhar A, Shaw G, Kelly JD, Pye H, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: haider a. Sci Rep. 2020 Sep 1;10(1):14380. doi: 10.1038/s41598-020-71263-9. Sci Rep. 2020. PMID: 32873828 Free PMC article.
1,338 results